

- #ABBOTT DIAGNOSTICS STREGNTHS FULL#
- #ABBOTT DIAGNOSTICS STREGNTHS SERIES#
- #ABBOTT DIAGNOSTICS STREGNTHS FREE#
Regularly make decisions which impact quality, time, or cost.

#ABBOTT DIAGNOSTICS STREGNTHS FREE#
#ABBOTT DIAGNOSTICS STREGNTHS FULL#
Our 115,000 colleagues serve people in more than 160 countries.Īt Abbott, you can do work that matters, grow, and learn, care for yourself and family, be your true self and live a full life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. "This agreement is not only a strategic business fit in expanding our companion diagnostics partnerships with leading pharmaceutical companies, but ultimately, it enables us to help improve the lives of cancer patients worldwide.Abbott is a global healthcare leader that helps people live more fully at all stages of life. "As a leading diagnostics partner in developing companion diagnostic tests, Abbott is excited to help bring new testing opportunities to the field of personalized medicine," said Deepak Nath, president, Molecular Diagnostics, Abbott. Biocartis' Idylla system features a unique, integrated, “sample in, result out” technology, to generate high quality molecular test results. Multiplexing, or the ability to analyze multiple molecular markers simultaneously, is important for pharmaceutical partners that need to analyze multiple biomarkers in their clinical trials and ultimately helps physicians obtain more useful information from limited patient samples. In partnership with pharmaceutical companies, Biocartis and Abbott will create various biomarker panels for use on the Idylla system, where each marker in the panel has a known clinical significance. We are excited to combine strengths with Abbott in order to make this new generation of diagnostic solutions available to patients globally." "Our Idylla system is extremely easy-to-use and provides rapid results, offering doctors quick and easy access to individual patient biomarker data anywhere and anytime.
#ABBOTT DIAGNOSTICS STREGNTHS SERIES#
"Much of the current molecular diagnostic practice involves a series of specialized, labor intensive and time-consuming steps," said Rudi Pauwels, CEO and Chairman, Biocartis.
